Spontaneous Neoplastic Lesions
in the CrI:CD-1(ICR) Mouse
in Control Groups from
18 Month to 2 year Studies
March, 2005
Information Prepared by
Mary L.A. Giknis Ph.D
Charles B. Clifford D.V.M, Ph.D
TABLE OF CONTENTS
INTRODUCTION............................................................................................................................ 1
PURPOSE ...................................................................................................................................... 1
COMMON STUDY PARAMETERS .................................................................................................. 1
DATA SETS PRESENTED.............................................................................................................. 1
SUMMARY TABLE CALCULATIONS ..............................................................................................2
Number of Studies (# Studies) ................................................................................................. 2
Total Number of Organs (Total # Organs) ................................................................................ 2
Total Number of Lesions (# Lesions) ........................................................................................2
Percent of Total ......................................................................................................................... 2
Number of Studies Using This Diagnosis ................................................................................. 2
Minimum and Maximum Percent Found (Minimum and Maximum % Found) ..........................2
ADDITIONAL INFORMATION .........................................................................................................3
SYNONYMS ................................................................................................................................... 3
ABBREVIATIONS ........................................................................................................................... 3
ACKNOWLEDGMENTS ................................................................................................................. 3
REQUEST FOR DATA ....................................................................................................................3
REFERENCES............................................................................................................................... 3
Table 1: Summary of Individual Study Information and Survival/Males ................................... 4
Table 2: Summary of Individual Study Information and Survival/Females ............................... 5
Graph 1: Male Survival — 78-104 Weeks.................................................................................6
Graph 2: Female Survival — 78-104 Weeks ............................................................................ 7
Table 3: Neoplasms/Males — 78-104 Weeks ...........................................................................8
Table 4: Neoplasms/Females — 78-104 Weeks .....................................................................11
Table 5: Incidence of Neoplasms by Study for Selected Organs/Males ................................16
Table 6: Incidence of Neoplasms by Study for Selected Organs/Females ............................ 18
INTRODUCTION
The data presented in these tables was gathered from 59 toxicology studies of at least 78 weeks duration.
All studies were performed in the United States or Europe by contract laboratories or industrial toxicology
facilities.
PURPOSE
The purpose of this compilation is to offer the study director, reviewing toxicologist and/or study pathologist
some reported incidences of neoplasms in Crl:CD1(ICR) mice, maintained as control animals, in studies of
78-104 weeks duration. Diagnoses in this compilation are intentionally grouped in a manner to provide the
user with a range of reported incidences of similar types of lesions. This compilation is not intended in any
way to propose a system of standardized nomenclature nor does it separately include each and every
variant of the lesion.
COMMON STUDY PARAMETERS
The 59 studies included in this publication were initiated between 1987 and 2000 in 11 different laboratories.
All studies used male and/or female Crl:CD1(ICR) mice from four different Charles River Laboratories
production sites: Raleigh, North Carolina; Stone Ridge, New York; Kingston, New York and Portage Michigan.
The mice in these studies were from control groups of dietary or gavage studies and were approximately 4-7
weeks of age at study initiation. Some groups were untreated while others received the study vehicle; all
served as control groups.
The mice included in this publication were generally singly housed in hanging wire mesh cages, fed a diet
of Purina 5002 Certified Rodent Chow and had free access to water. The animal rooms were generally
maintained at average temperatures of 72 +/- 5 degrees Fahrenheit with an average relative humidity of
30-70%. A 12hr/12hr light/dark cycle was employed in all studies. Since these studies were conducted in
different facilities over a period of several years, there was some variation in environmental conditions. The
overall environmental conditions were not considered by those performing the studies to have had any effect
on the quality or integrity of the studies. Information on the health monitoring for adventitious infections, other
than that associated with pathological examination conducted in accordance with scheduled or moribund
sacrifices, was not available.
DATA SETS PRESENTED
Survival data are presented by study as the actual number surviving to terminal sacrifice and as a percent
survival at terminal sacrifice (Tables 1 and 2). The survival data are also presented in graphic form (Graphs
1 and 2). Terminal sacrifices in the studies reported were conducted between weeks 78 and 104 of study.
Actual study duration is included in Tables 1 and 2 and footnoted in Graphs 1 and 2. Survival data were not
available for all studies at the time of publication. Only those studies for which data were available are
represented on the graphs.
The overall incidences of all neoplastic lesions observed in any organ are reported and summarized by sex
in Tables 3 and 4. These data also include neoplastic lesions from mice that died or were found moribund
and killed prior to terminal sacrifice. Due to the apparent diversity in terminology and the variability among
studies in the incidence of particular lesions, the individual study incidences of lesions in selected organs/
systems are also presented (Tables 5 and 6). These organs/systems include liver, lung and whole body/
multiple organ.
1
SUMMARY TABLE CALCULATIONS
The following is a description of how each of the parameters in the tables was calculated.
Number of Studies (# Studies)
This is the number of studies in which a particular tissue/organ was examined. In this publication, the number
of studies is usually 52 for males and 54 for females. It is important for the reader to realize that some of the
studies reported in this document were performed in only males or females and occasionally a specific
tissue/organ was not examined in a particular study. The study identification number for females does not
necessarily correlate with the same study identification number in males.
Total Number of Organs (Total # Organs)
This number represents the sum of the total number of tissues or organs examined in all of the control
groups from all studies combined. Widespread tumors which showed involvement of multiple organs were
li sted on the basis of the total number of animals examined. Occasionally a tumor would be noticed in a
tissue not designated for histological examination by the study protocol. In these instances, the tumor
incidence was based on the total number of animals examined as any such tumor or lesion would have been
noticed on gross examination of the animal. Autolysis did not routinely exclude tissues from diagnosis.
Tissue numbers were adjusted only if the individual study table indicated that some tissues were missing or
inadequate for examination. Some laboratories presented data separately for different regions within a organ
(i.e., duodenum, jejunum, and ileum) while most presented data by the organ (i.e., small intestine). When
data were presented separately by organ region, it was grouped under the organ and calculations were
based on the number of organs examined.
Total Number of lesions (# Lesions)
This represents the total number of occurrences of this lesion in a specific organ in all studies examined.
Percent of Total
These values represent the particular incidence of a particular lesion/diagnosis in the total number (all
studies combined) of a particular organ examined. These values were calculated by dividing the total
number of lesions by the total number of organs/animals examined and then multiplying by 100 to express
the value as a percent. Values are expressed to the second decimal place. Some caution is indicated in
using this number, since not all pathologists or institutions will include all diagnoses in their lexicon.
Number of Studies Using This Diagnosis
This is the number of studies in which a particular diagnosis was reported. This number may be useful in
interpreting the overall incidence (percent of total) of a particular diagnosis, see above.
Minimum and Maximum Percent Found (Minimum and Maximum % Found)
The range reported is the lowest and highest percent incidence for each lesion from the studies where the
diagnosis was made. Therefore, if a study did not include a particular diagnosis, it was excluded from these
calculations. The Minimum and Maximum Percent Found values should be considered in conjunction with
the Number of Studies Using the Diagnosis.
The individual study percentages, Minimum % Found and Maximum % Found, were calculated by dividing
the number of times each diagnosis was made by the total number of organs examined in each study and
then multiplying the resultant value by 100 to express it as a percent. Values are expressed to the second
decimal place.
2
ADDITIONAL INFORMATION
If additional information is desired regarding the conduct of these studies or the incidence of a particular
neoplasm, please contact Mary Giknis through Charles River Laboratories Technical Support Services
(800.338.9680). We will gladly provide assistance if we are able.
SYNONYMS
Synonymous terms or diagnoses were frequently encountered in different studies and were combined under
a single, often broad diagnosis, which was considered to be the primary diagnosis. Although some effort was
made to use currently acceptable terms, it is beyond the scope of this publication to propose a system of
preferred diagnoses. The synonyms that were included in the various diagnoses are presented in the synonym
li st that follows. Where possible, terminology is consistent with the classification system proposed by the
Society of Toxicologic Pathologists.
Gallbladder: Adenoma = Papilloma
Skin: Papilloma = Squamous Cell Papilloma
Nerve Sheath Tumor = Schwannoma = Neurofibroma
Testis: Sertoli Cell Tumor, Benign = Sertoliform Adenoma
Epididymis: Fibrosarcoma = Stromal Sarcoma
Uterus: Endometrium, Adenocarcinoma = Endometrial Carcinoma
Endometrial Stromal Sarcoma = Endometrial Sarcoma
Whole Body/Multiple Organ:
Histiocytic Sarcoma = Lymphoma, Histiocytic = Fibrous Histiocytoma
Lymphoma, Lymphocytic = Leukemia, Lymphocytic
Lymphoma, Malignant = Lymphosarcoma
Mast Cell Tumor = Mastocytomacytoma
ABBREVIATIONS
NR = Not Recorded or not available at the time of publication.
ACKNOWLEDGEMENTS
Our special thanks to Joe Frank, Julie Delaney and Ajit Thakur and all of the contributing laboratories without
whose help this publication would not have been possible.
REQUEST FOR DATA
The purpose of these publications is to assist you, our clients, in evaluating your data. Our aim is to provide you
with the data that you need to do your job well. We welcome any suggestions that you may have to improve
this document as well as suggested topics for future documents. However, please realize that the publication
is only as good as the data. To this end we invite you to participate in and support this worthwhile project by
sending us your control data. If you or someone at your laboratory is willing to participate, please contact Mary
Giknis through Charles River Laboratories, 251 Ballardvale Street, Wilmington, MA 01887.
REFERENCES
1. Maronpot, R.R. (ed.). Patholoay of the Mouse, 1999, Cache River Press, Vienna, IL.
2. Mikaelian, I., et al., Diversity of spontaneous neoplasms in commonly used inbred strains and stocks of
laboratory mice, in The Laboratory Mouse, Hedrich, H. (ed.), 2004, Elsevier Scientific Press, Amsterdam.
3. Mohr, U. (ed.), Pathobiology of the Aging Mouse, Vols. 1 and 2, 1996, ILSI Press, Washington, D.C.
3
Table 1: Summary of Individual Study Information and Survival/Males
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
1
1987
53
NR
3
1988
50
NR
4
1988
49
NR
78
2
1988
47
40
85.1
78
6
1988
59
NR
7
1989
50
NR
78
5
1988
50
31
62.0
78
78
78
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
17
1992
50
35
70.0
78
18
1992
50
39
78.0
78
19
1992
50
NR
20
1992
50
NR
21
1993
50
NR
78
78
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
33
1993
70
17
24.3
104
34
1993
50
18
36.0
104
35
1993
65
24
36.9
104
36
1993
50
NR
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
49
1998
60
NR
50
1999
65
NR
51
1999
60
NR
104
104
104
52
2000
55
14
25.5
104
104
9
1989
50
NR
10
1990
48
NR
11
1990
50
NR
78
8
1989
60
45
75.0
78
13
1990
69
NR
78
12
1990
50
47
94.0
78
78
78
22
1993
50
NR
23
1993
60
NR
24
1993
50
NR
25
1994
50
NR
26
1995
70
NR
78
78
78
78
78
37
1994
50
22
44.0
104
38
1994
65
43
66.2
104
39
1994
65
28
43.1
104
40
1995
60
26
43.3
104
41
1995
60
29
48.3
104
15
1991
59
38
64.4
78
16
1991
60
NR
78
14
1991
50
31
62.0
78
78
27
1989
50
30
60.0
97
28
1992
49
39
79.6
100
29
1990
60
11
18.3
104
30
1991
70
40
57.1
104
31
1991
65
NR
104
32
1993
60
22
36.7
104
42
1995
60
NR
43
1995
80
NR
44
1996
50
27
54.0
104
45
1996
50
22
44.0
104
46
1996
116
NR
47
1996
60
NR
48
1996
70
NR
104
104
104
104
104
78
Table 2: Summary of Individual Study Information and Survival/Females
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
cn
1
1987
52
NR
78
2
1988
49
40
81.6
78
3
1988
50
NR
4
1988
48
NR
6
1988
60
NR
7
1989
50
NR
78
5
1988
49
33
67.3
78
78
9
1989
50
NR
10
1990
48
NR
11
1990
50
NR
78
8
1989
60
45
75.0
78
78
13
1990
70
NR
14
1991
49
31
78
12
1990
49
36
73.5
78
78
78
78
63.3
78
28
1995
75
47
62.7
94
44
1995
60
23
38.3
104
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
17
1992
50
39
78.0
78
18
1992
50
NR
19
1992
50
NR
20
1993
50
NR
21
1993
50
NR
22
1993
59
NR
23
1993
50
NR
24
1994
50
NR
25
1995
70
NR
26
1996
116
NR
78
78
78
78
78
78
78
78
91
27
1995
60
36
60.0
94
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
33
1991
65
NR
34
1992
150
NR
104
36
1993
70
13
18.6
104
37
1993
50
16
32.0
104
38
1993
65
20
30.8
104
39
1993
59
NR
104
35
1993
60
21
35.0
104
40
1994
50
22
44.0
104
41
1994
65
36
55.4
104
42
1994
65
28
43.1
104
43
1995
60
27
45.0
104
Study Identification
Study Initiation Date
Total Number on Study
Number Surviving to Termination
% Survival
Study Duration in Weeks
49
1996
60
NR
50
1996
70
NR
51
1998
60
NR
52
1999
65
NR
53
1999
60
NR
104
104
104
104
104
54
2000
55
18
32.7
104
104
15
1991
59
38
64.4
78
16
1991
60
NR
29
1989
50
37
74.0
97
30_
31
1992 1990
50
60
39
13
21.7
78.0
100
104
32
1991
70
31
44.3
104
45
1995
60
NR
46
1995
80
NR
104
104
48
1996
50
21
42.0
104
47
1996
50
21
42.0
104
78
Table 3: Neoplasms/Males - 78-104 Weeks
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
STOMACH
Nonglandular Mucosa /Squamous Cell Papilloma
Adenocarcinoma
52
SMALL INTESTINE
Adenoma
Adenocarcinoma
52
LARGE INTESTINE / CECUM / ANUS
Adenocarcinoma
52
LIVER
Hepatocellular Adenoma
Hepatocellular Carcinoma
Hemangioma
Hemangiosarcoma
52
GALLBLADDER
Adenoma
52
PERITONEUM
Fibrosarcoma
Lipoma
52
NASAL CAVITY
Nasal Adenocarcinoma
Squamous Cell Carcinoma
52
LUNG
Adenoma, Alveolar / Bronchiolar
Adenocarcinoma, Alveolar / Bronchiolar
Mesothelioma, Malignant
52
KIDNEY
Adenoma / Tubular Adenoma
Adenocarcinoma / Tubular Adenocarcinoma
52
URINARY BLADDER
Leiomyoma
Leiomyoblastoma, Malignant
Leiomyosarcoma
52
TESTIS
Interstitial Cell Tumor, Benign
Interstitial Cell Tumor, Malignant
Hemangioma
Hemangiosarcoma
Sertoli Cell Tumor, Benign
Sertoli Cell Tumor, Malignant
52
8
2916
3
2
0.10
0.07
3
2
1.67
1.79
1.72
1.82
2820
1
5
0.04
0.18
1
4
1.72
1.67
1.72
2.90
2851
3
0.11
2
1.43
4.08
2941
308
169
9
48
10.47
5.75
0.31
1.63
52
47
7
21
2.86
1.54
1.54
1.11
28.00
16.00
4.00
8.57
2596
11
0.42
8
1.52
5.00
2947
2
2
0.07
0.07
2
2
1.67
1.43
1.69
2.00
2946
1
1
0.03
0.03
1
1
2.00
1.69
2.00
1.69
2945
421
217
3
14.30
7.37
0.10
51
45
1
2.00
1.43
5.00
42.00
26.00
5.00
2939
7
4
0.24
0.14
5
4
2.00
1.43
4.00
2.00
2905
1
2
5
0.03
0.07
0.17
1
2
3
1.67
1.45
2.00
1.67
1.67
4.00
2946
25
3
2
2
3
1
0.85
0.10
0.07
0.07
0.10
0.03
20
3
2
2
3
1
1.43
1.43
1.67
1.43
1.43
1.43
5.00
2.00
2.00
1.67
1.69
1.43
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
SEMINAL VESICLE
Adenocarcinoma
Leiomyosarcoma
52
PROSTATE
Adenoma
52
EPIDIDYMIS
Adenoma
Fibrosarcoma
Hemangiosarcoma
Leiomyoma
52
SKIN
Papilloma
Trichoepithelioma, Benign
Chondroma
Fibroma
Fibrosarcoma
Granular Cell Tumor, Benign
Hemangioma
Hemangiosarcoma
Leiomyosarcoma
Mast Cell Tumor
Nerve Sheath Tumor, Benign
Nerve Sheath Tumor, Malignant
Sarcoma
52
ADRENAL
Cortex, Adenoma
Cortex, Carcinoma
Paragang l ioma
Pheochromocytoma, Benign
Subcapsular Cell, Adenoma
Spindle Cell Tumor, Benign
52
PANCREAS
Islet Cell, Adenoma
Hemangiosarcoma
52
PITUITARY
Adenoma
Carcinoma
Pars Intermedia, Adenoma
52
THYROID
C-Cell, Adenoma
Follicular Cell, Adenoma
Follicular Cell, Carcinoma
52
9
2912
1
1
0.03
0.03
1
1
2.00
1.67
2.00
1.67
2933
1
0.03
1
1.67
1.67
2885
1
3
1
1
0.03
0.10
0.03
0.03
1
3
1
1
2.00
1.43
1.54
1.67
2.00
1.67
1.54
1.67
2922
5
1
1
3
6
1
1
4
1
1
2
3
2
0.17
0.03
0.03
0.10
0.21
0.03
0.03
0.14
0.03
0.03
0.06
0.10
0.07
5
1
1
3
4
1
1
4
1
1
2
3
2
1.47
2.63
1.67
1.67
1.54
1.67
1.54
1.43
1.43
1.54
1.67
1.43
1.67
2.00
2.63
1.67
2.08
3.33
1.67
1.54
1.67
1.43
1.54
2.00
2.00
2.00
2896
33
1
1
11
2
6
1.14
0.03
0.03
0.38
0.07
0.21
20
1
1
7
2
4
1.56
2.00
1.67
1.11
1.43
1.56
7.14
2.00
1.67
5.00
1.54
4.00
2929
4
2
0.14
0.07
4
2
1.54
1.67
2.00
1.69
2874
8
2
1
0.28
0.07
0.03
6
2
1
1.45
1.67
2.00
3.33
2.04
2.00
2893
1
14
1
0.03
0.48
0.03
1
14
1
2.00
1.11
2.00
2.00
2.00
2.00
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
BRAIN
Hemangioma
Oligodendroglioma
Meningioma
52
BONE
Osteoma, Benign
Osteosarcoma
Sarcoma
52
BONE MARROW
Lymphoma, Malignant
Hemangiosarcoma
52
SPLEEN
Hemangioma
Hemangiosarcoma
Lymphoma, Malignant
52
THYMUS
Lymphoma, Malignant
52
LYMPH NODES
Hemangioma
Hemangiosarcoma
Lymphoma, Malignant
52
WHOLE BODY/MULTIPLE ORGAN
Lymphoma, Malignant
Lymphoma, Lymphocytic
Leukemia, Granulocytic
Hemangiosarcoma
Histiocytic Sarcoma
Mast Cell Tumor, Malignant
52
EYE
Harderian Gland, Adenoma
Harderian Gland, Adenocarcinoma
52
EAR
Pinna, Hemangioma
Pinna, Papilloma
52
10
2946
1
1
1
0.03
0.03
0.03
1
1
1
1.43
2.04
1.43
1.43
2.04
1.43
2940
1
1
1
0.03
0.03
0.03
1
1
1
1.43
1.54
1.43
1.43
1.54
1.43
2936
1
3
0.03
0.10
1
2
2.00
1.54
2.00
3.33
2913
10
35
4
0.34
1.20
0.14
9
19
1
1.43
1.54
8.00
4.00
8.00
8.00
2304
7
0.30
1
14.89
14.89
2874
3
3
3
0.10
0.10
0.10
3
3
1
1.43
1.67
6.00
2.04
2.00
6.00
2935
132
14
8
29
46
4
4.50
0.47
0.27
0.99
1.57
0.14
42
10
8
8
24
4
1.45
1.69
1.43
1.67
1.11
1.43
21.67
4.08
2.04
12.00
8.00
2.00
2907
152
12
5.23
0.41
39
8
1.67
1.43
18.64
8.33
2945
1
1
0.03
0.03
1
1
1.67
1.67
1.67
1.67
Table 4: Neoplasms/Females - 78-104 Weeks
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
LOCATION AND TUMOR
ORAL CAVITY
Tongue, Papilloma
SALIVARY GLAND
Sarcoma
54
_
54
3237
1
0.03
1
1.67
1.67
3239
1
0.03
1
1.67
1.67
3141
3
4
3
2
0.10
0.13
0.10
0.06
3
4
3
2
1.47
0.79
1.43
1.56
2.00
2.04
2.00
2.00
3030
1
3
0.03
0.10
1
3
1.18
1.49
1.18
2.00
3013
1
2
0.03
0.07
1
2
1.72
1.72
1.72
1.82
3110
31
20
1
8
25
1.00
0.64
0.03
0.26
0.80
23
15
1
8
15
0.85
1.43
1.54
1.54
1.43
7.84
4.29
1.54
2.00
6.15
2873
6
0.21
6
1.43
3.03
3211
1
0.03
1
1.54
1.54
STOMACH
Polypoid Adenoma
Squamous Papilloma
Squamous Cell Carcinoma
Undifferentiated Carcinoma
54
SMALL INTESTINE
Adenoma
Adenocarcinoma
54
LARGE INTESTINE / CECUM / ANUS
Leiomyoma
Leiomyosarcoma
54
LIVER
Hepatocellular Adenoma
Hepatocellular Carcinoma
Undifferentiated Carcinoma
Hemangioma
Hemangiosarcoma
54
GALL BLADDER
Adenoma
54
PERITONEUM
Myxosarcoma
54
NASAL CAVITY
54
3151
LUNG
Adenoma, Alveolar/Bronchiolar
Adenocarcinoma, Alveolar/Bronchiolar
Mesothelioma, Benign
Mesothelioma, Malignant
54
3143
299
145
1
2
9.51
4.61
0.03
0.06
49
41
1
1
1.67
0.77
1.67
3.33
26.67
18.37
1.67
3.33
KIDNEY
Adenoma/Tubular Adenoma
Adenocarcinoma/Tubular Adenocarcinoma
Transitional Cell Carcinoma
54
3227
1
1
1
0.03
0.03
0.03
1
1
1
2.00
2.00
2.00
2.00
2.00
2.00
11
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
URINARY BLADDER
Transitional Cell Carcinoma
Leiomyoma
Leiomyosarcoma
Undifferentiated Sarcoma, Malignant
54
OVARY
Adenoma
Cystadenoma
Granulosa Cell Tumor, Benign
Granulosa Cell Tumor, Malignant
Tubular Adenoma
Luteal Cell Tumor, Benign
Luteal Cell Tumor, Malignant
Sertoliform Adenoma
Theca Cell Tumor, Benign
Theca Cell Tumor, Malignant
Hemangioma
Hemangiosarcoma
Leiomyoma
Oviduct, Fibroma
54
UTERUS
Endometrium, Adenoma
Endometrium, Adenocarcinoma
Endometrial Stromal Polyp
Endometrial Stromal Sarcoma
Fibroma
Fibrosarcoma
Granular Cell Tumor, Benign
Hemangioma
Hemangiosarcoma
Leiomyoma
Leiomyosarcoma
Nerve Sheath Tumor, Malignant
Neurofibrosarcoma
Osteosarcoma
Deciduoma
54
CERVIX
Squamous Cell Carcinoma
Endometrial Stromal Polyp
Endometrial Stromal Sarcoma
Fibrosarcoma
Granular Cell Tumor, Benign
Hemangiopericytoma
Leiomyoma
Leiomyosarcoma
Lymphangioma
Myxoma
Schwannoma
54
12
3088
1
1
4
1
0.03
0.03
0.13
0.03
1
1
4
1
2.17
1.67
1.75
2.00
2.17
1.67
2.44
2.00
3104
7
23
9
1
22
8
1
2
7
2
8
5
4
2
0.23
0.74
0.29
0.03
0.71
0.26
0.03
0.06
0.23
0.06
0.26
0.16
0.13
0.06
3
14
8
1
13
7
1
2
7
2
7
5
4
2
1.67
1.54
1.47
1.67
1.43
1.43
1.11
2.00
0.77
1.43
1.11
1.43
1.69
0.77
4.69
7.27
2.86
1.67
8.16
4.00
1.11
2.04
2.04
2.04
2.90
2.00
2.13
2.04
3182
3
16
164
38
2
2
1
17
15
47
37
6
1
8
1
0.09
0.50
5.15
1.19
0.06
0.06
0.03
0.53
0.47
1.48
1.16
0.19
0.03
0.25
0.03
3
10
41
23
2
2
1
13
13
24
22
5
1
4
1
1.54
0.86
1.67
1.43
1.67
1.54
2.04
1.25
0.77
1.43
0.86
1.43
2.00
1.54
1.75
2.00
4.29
17.14
8.00
2.00
1.69
2.04
4.62
4.08
7.50
6.00
3.08
2.00
8.00
1.75
3078
5
9
6
3
1
1
13
21
1
1
2
0.16
0.29
0.19
0.10
0.03
0.03
0.42
0.68
0.03
0.03
0.06
5
8
6
3
1
1
11
14
1
1
2
1.15
1.15
0.80
0.80
1.75
1.75
0.80
1.45
2.04
2.00
1.75
2.00
3.33
2.04
1.69
1.75
1.75
4.17
5.08
2.04
2.00
2.00
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
VAGINA
Basal Cell Adenoma
Papilloma
Polyp
Adenocarcinoma
Fibrosarcoma
Leiomyoma
Leiomyosarcoma
54
CLITORAL GLAND
54
3141
SKIN
Basal Cell Tumor, Benign
Basal Cell Carcinoma
Squamous Cell Papilloma
Squamous Cell Carcinoma
Fibrosarcoma
Leiomyosarcoma
Liposarcoma
Myxosarcoma
Rhabdomyocarcoma
Sarcoma
Nerve Sheath Tumor, Malignant
54
MAMMARY GLAND
Adenoma
Adenocarcinoma
Adenoacanthoma
Adenoacanthoma, Malignant
Fibrosarcoma
54
ADRENAL
Cortex, Adenoma
Cortex, Adenocarcinoma
Pheochromocytoma, Benign
Pheochromocytoma, Malignant
Spindle Cell Tumor, Benign
54
PANCREAS
Acinar Cell Adenoma
Islet Cell, Adenoma
Islet Cell, Carcinoma
54
PITUITARY
Adenoma
Carcinoma
Pars Intermedia Adenoma
54
3114
1
2
4
1
1
7
3
13
0.03
0.06
0.13
0.03
0.03
0.22
0.10
1
2
3
1
1
6
2
1.67
1.67
0.78
2.04
1.43
1.47
2.08
1.67
2.04
2.86
2.04
1.43
3.33
3.33
3232
1
2
5
8
21
1
2
1
1
3
15
0.03
0.06
0.15
0.25
0.65
0.03
0.06
0.03
0.03
0.09
0.46
1
2
5
7
12
1
1
1
1
3
4
1.67
1.67
1.43
1.43
1.54
2.00
4.00
1.43
1.54
1.43
1.67
1.67
2.00
2.00
3.33
6.67
2.00
4.00
1.43
1.54
1.67
14.00
2962
3
49
1
5
3
0.10
1.65
0.03
0.17
0.10
3
26
1
3
2
1.75
0.78
1.79
2.08
2.04
2.63
8.33
1.79
3.85
2.35
3167
8
1
11
1
7
0.25
0.03
0.35
0.03
0.22
6
1
8
1
5
0.78
2.00
0.78
1.96
1.54
3.08
2.00
5.00
1.96
4.00
3144
2
8
1
0.06
0.25
0.03
2
7
1
1.54
1.54
1.67
2.00
2.86
1.67
3063
64
1
1
2.09
0.03
0.03
32
1
1
0.78
1.69
1.45
14.29
1.69
1.45
_
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
THYROID
C-Cell, Adenoma
C-Cell, Carcinoma
Follicular Cell, Adenoma
Follicular Cell, Carcinoma
54
PARATHYROID
Adenoma
54
BRAIN
Ependymoma
Meningeal Sarcoma
54
SKELETAL MUSCLE
Rhabdomyosarcoma
Carcinoma, Squamous Cell
Hemangiosarcoma
Sarcoma
54
BONE
Osteoma
Osteosarcoma
Fibrosarcoma
54
HEART
Hemangiosarcoma
54
BONE MARROW
Fibrosarcoma
Plasmacytoma
Liposarcoma
Hemangiosarcoma
54
SPLEEN
Hemangioma
Hemangiosarcoma
Leiomyosarcoma
54
THYMUS
Thymoma, Malignant
Lymphoma, Thymic
54
LYMPH NODES
Hemangioma
54
14
3102
2
2
11
3
0.06
0.06
0.35
0.10
1
2
11
3
3.33
2.00
0.77
1.43
3.33
2.00
2.08
1.67
2675
4
0.15
4
1.64
3.23
3153
1
1
0.03
0.03
1
1
1.43
2.04
1.43
2.04
3153
5
1
1
1
0.16
0.03
0.03
0.03
5
1
1
1
1.67
0.78
1.82
2.00
2.00
0.78
1.82
2.00
3184
10
5
1
0.31
0.16
0.03
8
5
1
1.43
1.43
1.56
3.08
2.00
1.56
3159
2
0.06
2
1.54
2.00
3187
1
1
1
5
0.03
0.03
0.03
0.16
1
1
1
4
1.54
2.04
1.67
1.43
1.54
2.04
1.67
3.08
3142
3
18
1
0.10
0.57
0.03
3
15
1
1.43
1.43
2.00
2.00
4.62
2.00
2774
2
1
0.07
0.04
2
1
1.49
1.89
2.00
1.89
3112
5
0.16
4
1.43
4.17
LOCATION AND TUMOR
TOTAL
#STUDIES
#ORGANS PERCENT USING THIS MINIMUM MAXIMUM
#STUDIES #LESIONS OF TOTAL DIAGNOSIS % FOUND % FOUND
WHOLE BODY/MULTIPLE ORGAN
Lymphoma, Malignant
Lymphoma, Lymphocytic
Histiocytic Sarcoma
Leukemia, Granulocytic
Mast Cell Tumor, Malignant
Hemangioma
Hemangiosarcoma
54
EYE
Harderian Gland, Adenoma
Harderian Gland, Adenocarcinoma
54
EAR
Squamous Cell Carcinoma
54
15
3192
317
44
157
7
3
4
25
9.93
1.38
4.91
0.22
0.09
0.13
0.78
45
7
42
5
3
3
9
1.67
1.54
1.67
0.77
1.54
1.43
1.67
50.00
27.45
18.33
4.08
2.00
2.67
12.00
3103
75
9
2.42
0.29
35
9
1.35
1.43
8.33
2.38
3241
1
0.03
1
2.00
2.00
Table 5: Incidence of Neoplasms by Study for Selected Organs / Males
Study Identification
Study Duration (wks)
1
78
2
78
3
78
4
78
5
78
6
78
7
78
47
7
6
50
5
1
49
7
1
50
3
2
59
7
50
3
1
8
78
9
78
10
78
11
78
12
78
13
78
14 15
78 78
16 17
78 78
50
5
1
50
2
1
68
11
6
50
3
2
60
3
2
LIVER
Hepatocellular Adenoma
Hepatocellular Carcinoma
Hemangioma
Hemangiosarcoma
53
4
4
LUNG
Adenoma, Alveolar/Bronchiolar
Adenocarcinoma,
Alveolar/Bronchiolar
Mesothelioma, Malignant
53
6
1
47
9
1
50
9
3
49
10
1
50
1
4
58
5
2
50
6
5
60
6
3
50
48
10
3
50
3
50
8
69
15
16
50
6
59
8
1
WHOLE BODY/MULTIPLE
ORGAN
Lymphoma, Malignant
Lymphoma, Lymphocytic
Leukemia, Granulocytic
Hemangiosarcoma
Histiocytic Sarcoma
Mast Cell Tumor, Malignant
53
47
50
49
50
59
50
60
50
46
50
50
69
50
59
2
2
1
4
1
3
1
2
2
2
2
1
2
1
2
1
1
2
1
2
1
60
3
4
50
2
1
47
2
2
1
2
1
1
2
1
59
9
2
1
2
20 21
78 78
22
78
23
78
24
78
25 26
78 78
49
2
4
50
3
2
50
3
2
60
3
1
50
6
50
6
1
60
8
2
50 , 50
12
6
3
4
1
2
50
5
60
3
50 , 50
13
7
3
5
50
1
6
49
2
3
50
2
3
50
2
3
60
4
4
50
8
3
50
9
1
60
7
60
50
50
50
50
50
50
50
50
60
1
1
1
1
1
18 19
78 78
7
50
2
1
1
1
3
1
Table 5: Incidence of Neoplasms by Study for Selected Organs / Males (cont'd)
Study Identification
Study Duration (wks)
LIVER
Hepatocellular Adenoma
Hepatocellular Carcinoma
Hemangioma
Hemangiosarcoma
LUNG
Adenoma, Alveolar/Bronchiolar
Adenocarcinoma,
Alveolar/Bronchiolar
Mesothelioma, Malignant
WHOLE BODY/MULTIPLE
27
28
29
30
31
32
33
34
35
36 37
38
39 40
42
41
43 44
45
46 47
48 49
50
51
52
97 100 1 04 104 1 04 1 04 1 04 104 104 1 04 104 104 104 1 04 104 104 1 04 1 04 104 104 104 104 1 04 104 104 104
50
7
3
49
3
5
2
50
14
13
49
12
6
60
3
4
67
4
10
60
15
2
59
4
8
70
3
4
3
1
1
2
3
60
5
69
11
6
60
2
3
60
6
6
70
8
12
50
8
3
2
65
13
1
1
50
8
8
50
7
2
65
3
65
8
5
60
8
1
60
11
2
1
60
5
4
1
50
4
7
65
6
8
50
6
6
50
13
3
65
14
7
65,
17
2
60
10
4
60
11
1
60
14
4
70
2
6
2
3
50 , 50
14
6
4
5
70
15
1
50
13
3
50
21
4
90
7
5
60
7
2
1
3
90
6
10
60
5
8
60
10
7
60
11
6
65
6
6
70
2
7
60
11
9
55
3
2
5
6
4
1
65
11
4
70
14
8
60
5
8
55
7
6
3
_
49
49
60
70
60
60
70
4
2
6
13
5
50
65
50
50
65
65
60
60
60
70
50
50
90
60
60
65
70
60
55
2
4
5
3
5
3
2
4
1
5
5
7
2
7
4
2
1
1
1
4
5
1
3
4
4
2
6
6
ORGAN
Lymphoma, Malignant
Lymphoma, Lymphocytic
Leukemia, Granulocytic
Hemangiosarcoma
Histiocytic Sarcoma
Mast Cell Tumor, Malignant
3
1
1
1
2
1
1
1
3
2
2
2
2
1
1
1
2
1
1
4
1
1
3
1
3
2
1
2
Table 6: Incidence of Neoplasms by Study for Selected Organs / Females
Study Identification
Study Duration (wks)
1
78
2
78
3
78
4
78
5
78
6
78
7
78
8
78
LIVER
Hepatocellular Adenoma
Hepatocellular Carcinoma
Undifferentiated Carcinoma
Hemangioma
Hemangiosarcoma
52
49
50
47
49
1
60
1
50
1
57
LUNG
Adenoma, Alveolar/Bronchiolar
Adenocarcinoma,
Alveolar/Bronchiolar
Mesothelioma, Benign
Mesothelioma, Malignant
52
3
49
6
3
50
6
4
48
5
1
49
2
3
60
2
2
50
5
4
57 50
6
2
4
WHOLE BODY/MULTIPLE
ORGAN
Lymphoma, Malignant
Lymphoma, Lymphocytic
Histiocytic Sarcoma
Leukemia, Granulocytic
Mast Cell Tumor, Malignant
Hemangioma
Hemangiosarcoma
52
49
50
48
50
60
50
58 50
2
2
7
6
1
5
7
9
78
49
10
78
11
78
12
78
13
78
14
78
15
78
47
50
49
70
48
59
1
1
2
1
1
3
1
10
5
1
2
16
78
60
2
17
78
18
78
19
78
20
78
21
78
50 49
1
1
49
1
1
50
1
50
22
78
59
23 24
78 78
25 26
78 91
27
94
50
58
59
50
85
1
1
1
1
1
1
48
3
5
50
5
49
5
1
70
11
7
49
3
59
6
2
60
5
50
8
3
50
3
6
50
2
1
50
2
2
50 59
2
2
5
50
6
1
50
2
1
60
1
89
2
3
59
3
47
50
49
70
49
59
60
50
50
50
50
50
59
50
50
60 116
60
5
4
2
6
4
3
1
3
3
9
3
1
1
3
9
2
2
2
1
2
2
2
1
1
3
5
1
1
2
1
9
2
_
1
2
1
1
Table 6: Incidence of Neoplasms by Study for Selected Organs / Females (cont'd)
Study Identification
Study Duration (wks)
28
94
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
97 100 104 104 104 104 1 04 1 04 1 04 104 1 04 104 1 04 , 104 1 04 104 1 04 1 04 1 04 1 04 104 104 104 104 104 104
LIVER
Hepatocellular Adenoma
Hepatocellular Carcinoma
Undifferentiated Carcinoma
Hemangioma
Hemangiosarcoma
75
1
LUNG
Adenoma,
Alveolar/Bronchiolar
Adenocarcinoma,
Alveolar/Bronchiolar
Mesothelioma, Benign
Mesothelioma, Malignant
75
9
WHOLE BODY/MULTIPLE
ORGAN
Lymphoma, Malignant
Lymphoma, Lymphocytic
Histiocytic Sarcoma
Leukemia, Granulocytic
Mast Cell Tumor, Malignant
Hemangioma
Hemangiosarcoma
75
50
50
60
70
60 130
60
70
50
65
6
2
3
6
3
12
35
10
17
13
7
3
50
1
50
1
49
6
50
7
9
3
60
70
2
1
58 117
1
1
2
59
1
70
1
3
50
65
51
4
50 , 65
1
1
65
1
1
1
1
1
2
1
60
70
1
2
1
3
60 . 130
2
9
60
70
5
1
60
1
41
3
59
2
70
50
2
1
50
1
60
1
70
2
1
60
65
1
1
4
1
3
60
1
1
55
1
50
5
65
4
51 50
2
8
65
8
65
10
60
16
46
9
60
7
70
7
50
9
50
12
60
11
70
10
60
10
65
16
60
6
55
10
4
6
3
3
2
5
3
3
2
1
3
5
12
4
5
4
2
1
2
3
11
51
50
65
65
60
60
60
5
8
10
5
8
6
14
5
5
1
1
9
1
11
2
3
8
2
1
4
5
1
7
4
3
75
50
50
16
6
3
6
1
2
1
70
10
8
7
1
2
4
60
2
4
3
6
60
65
60
55
12
10
14
7
4
7
5
2
1